FAQ · 06
BPC-157 TB-500, answered from the literature
Twenty-five questions on the Wolverine blend — definitional, mechanistic, safety, dosing, and regulatory — each answered directly and cited where the claim is quantitative.
Identity and definitions
The first set of BPC-157 TB-500 questions is definitional: what the blend is, what each constituent is, and how the two differ.
Mechanism and evidence
These questions cover how each peptide works, whether they act through the same pathway, and what the combination evidence actually shows.
Safety questions
The safety questions are answered honestly against a thin record: there is no controlled human safety dataset for the blend, and one preclinical signal — tumor angiogenesis — is worth naming.
Dosing, half-life, and handling
These answers are research-context only. They report study parameters and handling practice, never human dosing guidance. Full detail sits on BPC-157 TB-500 dosage in the research literature.
Regulatory and access
The regulatory answers reflect the present-tense FDA record. Full context, cited to FDA, is on Wolverine legal status and FDA 503A compounding access.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack." It is not a single chemical entity and not an approved product. The two peptides are combined without any standardized, clinically validated ratio [9].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide — the cytoprotective and angiogenic component [1]. TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4 — the cytoskeletal, cell-migration component [3][6]. Together they form the Wolverine blend.
What is the BPC-157 and TB-500 blend used for in research?
In animal models the individual constituents have been studied for tendon, ligament, muscle, and wound repair [1][4]. All efficacy data are preclinical and single-compound; no study has evaluated the blend itself in humans [7].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The stated rationale is complementary mechanisms: BPC-157 supplies a local angiogenic and cytoprotective signal while TB-500 supplies an actin-sequestration and cell-migration signal [2][3]. This "synergy" is a theoretical extrapolation, not a finding from any controlled combination study [4].
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-mer derived from a gastric-juice protein, acting via VEGFR2-Akt-eNOS signaling [2]. TB-500 is a 7-mer fragment of Thymosin Beta-4, acting via G-actin sequestration [3]. They differ in structure, size, and mechanism, and their pathways are largely non-overlapping.
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it — structurally confirmed for Thymosin Beta-4 by 2 Å crystallography of an actin complex — regulating the cytoskeletal dynamics that drive cell migration [3]. Most efficacy data attributed to TB-500 used the full-length parent protein [4].
How does BPC-157 work compared to TB-500?
BPC-157 acts as a local angiogenic and cytoprotective signal, up-regulating VEGFR2 with downstream Akt-eNOS activation [2], whereas TB-500 acts intracellularly by sequestering G-actin [3]. The two pathways are largely non-overlapping, which is the basis of the complementary-mechanism rationale.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
In animal and in-vitro models, yes, by different routes: BPC-157 via VEGFR2 up-regulation and Akt-eNOS signaling [2], and thymosin beta-4 via endothelial migration [4]. Both are preclinical mechanisms, not clinical demonstrations of a combined effect.
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together, and the 2025 systematic review of BPC-157 makes no mention of TB-500 or any combination use [4][7]. The synergy claim extrapolates from each peptide's separate mechanism.
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are thin — three small BPC-157 pilots, and full-length Thymosin Beta-4 (not the TB-500 fragment) studies on the TB-500 side [4][9].
What are the side effects of BPC-157 and TB-500?
No controlled human safety dataset exists for the blend. A 2026 review of unapproved musculoskeletal peptides notes that rigorous human safety data are scarce and that such peptides carry a potential for serious harm while operating largely outside regulatory oversight [8]. The combination's safety profile is unproven.
Does TB-500 cause cancer or promote tumor growth?
Thymosin beta-4 is implicated in tumor angiogenesis and metastasis, so the same pro-migratory, pro-angiogenic properties that aid repair could in theory support tumor progression — a concern that compounds when two pro-repair peptides are combined [4][8]. This is an unresolved preclinical safety consideration, not a demonstrated clinical effect of the blend.
Is the BPC-157 / TB-500 blend safe for long-term use?
Long-term human safety is unknown. BPC-157 has only three small human pilot studies [9], the TB-500 heptapeptide has no completed controlled human trials [4], and the two have never been studied together long-term in people [7]. Nothing in the record supports a long-term-safety claim.
Is TB-500 bad for your heart?
There is no validated human cardiac safety data for TB-500 or the blend. Thymosin beta-4's vascular and migratory effects are studied preclinically, and a chronic mdx-mouse study found it did not improve cardiac function [4]. The combination's cardiovascular safety is unproven.
What is the half-life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported as under 30 minutes in an animal PK study [9]. No validated human half-life exists for either constituent at research doses, and none for the blend; human data on full-length Thymosin Beta-4 show dose-proportional PK but no established figure for the TB-500 fragment [4].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [9]. In unregulated material the product identity, purity, and actual BPC-157:TB-500 ratio are not guaranteed. This describes handling practice, not a preparation instruction.
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis; research doses are reported per body weight in animal models only [9]. Nothing here is administration guidance.
How do you cycle BPC-157 and TB-500?
No validated cycling protocol exists. Fixed-ratio vials (e.g. 10 mg + 10 mg) and loading/maintenance schedules circulate in the community without any controlled human-trial basis [9]. The non-monotonic 18 mg/kg-no-benefit stroke result argues against "more is better" loading logic [4].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical and microscopic measures, and improved healing of a transected rat medial collateral ligament in the broader literature [1]. These are preclinical, single-compound findings, not blend efficacy in humans [7].
Does BPC-157 and TB-500 help muscle tears and recovery?
A 2025 systematic review found BPC-157 "shows promise" for musculoskeletal recovery but only from the lowest tiers of evidence (level IV-V) and with no clinical safety data [7]. No human blend data exist, and chronic thymosin beta-4 did not improve strength in an mdx-mouse model [4].
Does the BPC-157 TB-500 blend help wound healing?
Thymosin beta-4 accelerated re-epithelialization and collagen deposition in animal wound models and reduced myofibroblast number, suggesting less scarring [4]. These are single-compound preclinical findings, largely from the full-length parent protein, not blend data in humans.
Are BPC-157 and TB-500 FDA approved or banned by WADA?
The FDA safety-risk page marked current through April 22, 2026 records that the BPC-157 and TB-500 nominations were withdrawn by their nominators; both peptides are no longer in Category 2, the agency's safety concerns remain on display, and FDA has not stated what the withdrawals mean for pharmacy compounding [10]. Both are also WADA-prohibited: BPC-157 under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories, banned in and out of competition for the relevant classes.
Is Wolverine legal?
Neither constituent is an FDA-approved drug, and the blend has no approved indication anywhere [10][11]. FDA's page no longer shows either one in 503A Category 2 — both nominations are recorded as withdrawn — and FDA has not spelled out what that means for compounding [10]; both are also WADA-prohibited in sport. The lawful compounded pathway requires a licensed-prescriber evaluation and a valid prescription.
Can you get BPC-157 from a compounding pharmacy?
FDA's safety-risk page records that BPC-157's nomination was withdrawn by its nominators and that the peptide is no longer in Category 2; the safety rationale remains, and FDA has not explained how a 503A pharmacy should read the withdrawal [10]. BPC-157 also appeared as a candidate on the July 23-24, 2026 PCAC agenda, and FDA had released nothing on the committee's votes as of September 2026 [12].
What is the FDA 503A status of Wolverine?
For both Wolverine constituents, FDA's safety-risk page records that the nominations were withdrawn by their sponsors; both peptides are no longer in Category 2, and FDA has not explained what that record allows a compounding pharmacy to do [10]. Both sat on the July 23-24, 2026 PCAC agenda as substances being considered for the 503A bulks list; agency staff had recommended against listing them, and FDA has posted no decision since [12].